Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Specificity and Use
CD15 stains a variety of tumor cells, including breast and lung cancer cells. In a series of 98 breast tumors, CD15 stained 35% of breast carcinomas, 60% of hyperplasias and 45% of normal breast tissues. In the breast, CD15 expression is closely associated with the leading edge of invasive tumors. In non-small cell lung cancers, CD15 stained 56% of adenocarcinoma and 45% of squamous cell carcinoma in one study. As CD15 stained adenocarcinoma but not mesothelioma, it has been used as part of an antibody panel to distinguish adenocarcinoma from malignant mesothelioma.
Suitable for use in Immunohistochemistry. Immunohistochemistry: 1:50-1:200. Epitope retrieval not required but enzyme digestion may enhance staining. Positive control: Human spleen.
PBS, pH 7.2, 1% BSA, 0.1% sodium azide.
For research use only.
About SSEA-1 / Lewis x / CD15
Also known as CD15, Lewis x, and 3-fucosyl-N-acetyl-lactosamine. It is synthezised by Fucosyltransferase 4 (FUT4).